{"id":234168,"date":"2026-03-27T11:04:17","date_gmt":"2026-03-27T16:04:17","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/03\/triple-pre-surgery-therapy-may-boost-immunity-against-soft-tissue-sarcoma"},"modified":"2026-03-27T11:04:17","modified_gmt":"2026-03-27T16:04:17","slug":"triple-pre-surgery-therapy-may-boost-immunity-against-soft-tissue-sarcoma","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/03\/triple-pre-surgery-therapy-may-boost-immunity-against-soft-tissue-sarcoma","title":{"rendered":"Triple pre-surgery therapy may boost immunity against soft tissue sarcoma"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/triple-pre-surgery-therapy-may-boost-immunity-against-soft-tissue-sarcoma.jpg\"><\/a><\/p>\n<p>Early results from preclinical studies and a clinical trial led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center and Stanford Medicine suggest that combining targeted radiation therapy with an experimental immune-boosting drug called BO-112 and anti-PD-1 therapy before surgery may help the immune system fight aggressive soft tissue sarcomas.<\/p>\n<p><a href=\"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/doi\/10.1158\/2159-8290.CD-25-1132\/774987\/Neoadjuvant-BO-112-and-hypofractionated-radiation\" target=\"_blank\">The findings<\/a>, published in <i>Cancer Discovery<\/i>, show that the approach can reshape the <a href=\"https:\/\/medicalxpress.com\/news\/2025-12-preoperative-antitumor-immune-response-common.html?utm_source=embeddings&utm_medium=related&utm_campaign=internal\" rel=\"related\">tumor microenvironment<\/a> to activate the body\u2019s immune cells against cancer.<\/p>\n<p>Soft tissue sarcomas are a rare and often hard-to-treat group of cancers that typically require a combination of surgery, radiation therapy and other systemic treatments. However, these tumors may still be resistant to standard therapies, highlighting the need for new treatment strategies.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Early results from preclinical studies and a clinical trial led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center and Stanford Medicine suggest that combining targeted radiation therapy with an experimental immune-boosting drug called BO-112 and anti-PD-1 therapy before surgery may help the immune system fight aggressive soft tissue sarcomas. The findings, published in [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,1495],"tags":[],"class_list":["post-234168","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-health"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/234168","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=234168"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/234168\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=234168"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=234168"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=234168"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}